In this study, we investigated the synergistic anti-tumor effects of PRG4 and regorafenib in both in vivo orthotopic intrahepatic HCC xenografted tumors and in vitro three-dimensional tumorspheres. This evidence concerns the gene PRG4 and neoplasm.